Nivolumab/pembrolizumabMyasthenia gravis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1751卷 / 1期

关键词：

D O I：

10.1007/s40278-019-61433-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：300 / 300

相关论文

共 50 条

[31] Ipilimumab/pembrolizumabMyasthenia gravis and myositis: case report
Reactions Weekly, 2018, 1728 (1) : 201 - 201
[32] PembrolizumabMyasthenia gravis flare and myocarditis: case report
Reactions Weekly, 2022, 1912 (1) : 373 - 373
[33] PembrolizumabMyasthenia gravis, hepatitis and thyroiditis: case report
Reactions Weekly, 2019, 1754 (1) : 277 - 277
[34] Methylprednisolone/pembrolizumabMyasthenia gravis and lack of efficacy: case report
Reactions Weekly, 2022, 1917 (1) : 369 - 369
[35] PembrolizumabMyasthenia gravis, successfully treated with rituximab: case report
Reactions Weekly, 2018, 1719 (1) : 181 - 181
[36] Carboplatin/paclitaxel/pembrolizumabMyasthenia gravis and treatment failure: case report
Reactions Weekly, 2023, 1954 (1) : 145 - 145
[37] BBIBP-CorV/pembrolizumabMyasthenia-gravis: case report
Reactions Weekly, 2024, 2039 (1) : 97 - 97
[38] Immune-globulin/pembrolizumabMyasthenia gravis and lack of efficacy: case report
Reactions Weekly, 2023, 1980 (1) : 211 - 211
[39] PembrolizumabMyasthenia gravis
Reactions Weekly, 2024, 2013 (1) : 345 - 345
[40] PembrolizumabMyasthenia gravis and myositis
Reactions Weekly, 2024, 2015 (1) : 350 - 350

← 1 2 3 4 5 →